Estrella Immunopharma宣布,其关于Eb103药物的Starlight-1一期临床试验数据,已被选为2026年美国移植与细胞治疗学会(ASTCT®)及国际血液与骨髓移植研究中心(CIBMTR®)联合会议的“突破性进展”口头报告。
Estrella Immunopharma宣布,其关于Eb103药物的Starlight-1一期临床试验数据,已被选为2026年美国移植与细胞治疗学会(ASTCT®)及国际血液与骨髓移植研究中心(CIBMTR®)联合会议的“突破性进展”口头报告。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.